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Atypical hemolytic uremic syndrome (aHUS) is characterized by microangiopathic 
hemolytic anemia, thrombocytopenia, and acute renal failure caused by a dysregulation 
in the complement system, specifically in the alternative pathway. These abnormalities 
are due to a genetic mutation in half of the cases, and the response to the treatment and 
the prognosis vary accordingly to which regulatory mechanism is impaired. Endothelial 
cell swelling and detachment, arterial wall thickening, namely glomerular capillary wall 
and mesangiolysis are the main renal histologic findings. The first step in patient 
approach will be the exclusion of other thrombotic microangiopathies such as typical 
hemolytic uremic syndrome (STEC-HUS), thrombotic thrombocytopenic purpura (TTP) 
among others since the clinical presentation is very similar. The treatment of aHUS 
consists in supportive measures namely plasma exchange, which should be started 24 
hours of the patient´s presentation. Eculizumab, a recombinant humanized monoclonal 
antibody, is the only agent approved for the treatment of non-Shiga toxin by FDA, 
which effectiveness has been reported. In those studies, eculizumab led to improvement 
of hematologic manifestations and renal function, cessation of plasma therapy, 
including in several cases that had not responded to plasma exchange. Renal 
transplantation is an option for patients that develop end-stage renal disease, albeit the 
high recurrence rates, and hepatic transplantation is reserved for special cases.  
 The high mortality and morbidity contributes for the poor prognosis of these group of 
patients. This article will approach the general characteristics of aHUS, its treatment 
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options, the correct management and monitoring of the disease response, the outcomes 
and the proposed recent therapies.  
KEYWORDS: Atypical hemolytic uremic syndrome; complement system; plasma 
therapy; eculizumab; renal transplantation. 
INTRODUCTION 
Hemolytic uremic syndrome (HUS) belongs to the large and diverse group of the 
thrombotic microangiopathies (TMAs) and is a life-threatening disorder characterized 
by a microangiopathic hemolytic anemia (MAHA), nonimmune, thrombocytopenia, and 
acute renal failure.(1, 2) We can consider two types of HUS. The most common (with a 
frequency of more than 90%) is classified as typical HUS or Shiga toxin-producing 
Escherichia coli HUS (STEC-HUS) and is due to a bacterial infection producing a 
Shiga-like toxin (Stx1 and Stx2), most frequently due to O157:H7 serotype 
enterohemorrhagic Escherichia coli infection.(3) It is more frequent in pediatric age, and 
often results in diarrhea, with favorable prognosis since as many as 70-85% of patients 
recover renal function.(4) 
The others 10% of all cases of the HUS are categorized as atypical HUS (aHUS), a rare 
disorder caused by a dysregulation of the complement alternative pathway due to an 
impairing of the regulatory mechanisms. The outcome is poor due to the high risk of 
progression to end-stage renal disease (ESRD) and death.(5)  
More than 50% of the aHUS cases have genomic defects and/or autoantibodies against 
complement regulatory proteins.(6, 7) The penetrance of the disease is reported as 
incomplete in all predisposing genes, highlighting the requirement of a precipitating 
event like drugs, autoimmune conditions, cancer, transplants, pregnancy, or metabolic 
conditions, for disease manifestation.(8) 
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When it comes to treating a patient with aHUS treatment should be applied as sooner as 
possible. Plasma therapy (PT) remains the initial treatment, preferably with intensive 
plasma exchange (PE) at high volumes and with a variable frequency, based on disease 
activity.(9) The clinical response after 5-7 days of daily PE treatment should aid further 
decisions since the complete hematological and renal recovery rates are usually below 
50% and differ according to the type of mutations or the levels of antibody titers.(5, 9)  
The discovery that complement system played an important role in aHUS led to the 
development of complement-inhibiting therapy.(9) Eculizumab, a humanized 
monoclonal antibody against C5, blocks the formation of the membrane attack complex 
(MAC), stopping the hemolytic process, allowing the interruption of PT for long-term, 
with improvements in renal function and in the prognosis.(6)  
Other options like renal and/or liver transplantation, could also be considered. New 
therapeutic strategies are also being studied. (1, 2) 
EPIDEMIOLOGY 
The information available about the epidemiology of aHUS is limited, but a multicenter 
study in Europe stated an aHUS incidence of 0.11 cases/million habitants and according 
to the European Medicines Agency (EMA) the prevalence may be of 3.3 
patients/million habitants/year among patients <18 years old, corresponding to 40 to 
60% of all aHUS cases. Male and female are equally affected but the prevalence rises 
among women when the disease develops in adulthood.(6, 10) 
PATHOGENESIS 
The complement system is part of the innate system but it also participates in the 
adaptive immunity. It’s activated by the classical, the lectin or by the alternative 
pathway.(8) The last one is constantly low-activated in plasma, and regulation defects or 
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over-activation ones, lead to cellular attack amplification, culminating in cell apoptosis 
and tissue damage, as seen in aHUS.(2, 8) This complex mechanism has also multiple 
amplification loops which help maintaining the disease process, as seen on Fig. 1. 
The regulation of the complement system is performed by membrane proteins such as 
factor H, CD35 (complement receptor type 1), CD46 (MCP), CD55 (decay accelerating 
factor) that act as cofactors for plasma protein factor I leading to the cleavage of C3b to 
inactive C3b and dissociating C3 and C5 convertases. This regulation is also 
accomplished by CD59 (MAC-inhibitory protein), another membrane protein, which 
promotes the cessation of the lytic membrane attack complex.(2, 11)  
Genetic mutations have been described in 50 to 60% of aHUS, comprising both familial 
and sporadic forms.(2, 6)  
Familial cases represent less than 20% of aHUS patients with both dominant and 
recessive hereditary forms described. Autossomal recessive aHUS often occurs in 
childhood. On the other hand, autossomal dominant aHUS affects mainly adults.(12)  
Nearly 50% of the sporadic forms appear to be idiopathic.(2)  
The activity of the complement regulatory proteins can be decreased by loss-of-function 
mutations (CFH, CFI, CD46, and THBD) or due to autoantibodies against complement 
factor I or factor H. The occurrence of these antibodies has an association with the 
homozygous CFHR1-3 deletion, showing that they aren’t strictly acquired. Conversely, 
the increase of the complement alternative pathway activation can also occur by gain-
of-function mutations in CFB or C3.(5)  
Mutations in a non-complement protein, including diacylglycerol kinase ᶓ, plasminogen 
and factor XII, have also been recognized, and in some cases in association to factor H 
autoantibodies.(11, 13)  
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More than 3% of the patients with aHUS have combined mutations.(6)  
The penetrance of the disease is incomplete since only 50% of the mutations carriers 
manifest aHUS. However, the percentage can increase in patients with combined 
mutations. (8, 10)  
Patients who are carriers of complement mutations may stay asymptomatic for decades, 
suggesting that a trigger seem be essential for disease manifestation.(1, 2) aHUS can be 
triggered by infections, pregnancy or post-partum period, autoimmune diseases, cancer, 
bone marrow or solid organ transplantation, and drugs such as immunotherapeutic 
agents (calcineurin inhibitors or the mammalian target of rapamycin inhibitors 
(mTORi)), platelet antiaggregants (e.g., ticlopidine and clopidogrel), antivirals, oral 
contraceptive drugs and chemotherapeutic drugs.(8, 14, 15) Infections are responsible for at 
least half of these cases, mostly upper respiratory tract infections (influenza H1N1 
virus) or non-E. coli diarrhea/gastroenteritis.(6, 8) Pregnancy, mostly during post-partum 
period, is a frequent trigger of aHUS among women.(16) The prevalence, mechanisms, 
response to treatment and prognosis differ to each mutation, as shown in Tab.1. 
The hemolysis and the formation of microthrombi in aHUS can be explained by the 
effects that complement system has on platelets, red cells and endothelial cells. The 
complement activation can be induced by endothelial cell damage, promoting damage-
induced enhancement of complementary activation and culminating in further damage 
of nearby cells as shown on Fig.2. Although this activation is more probable to happen 
via the alternative pathway in aHUS, classical and lectin pathways can also participate 
because of the exposure of novel epitopes recognized by both. Nonetheless, it was not 
identified yet which cells are damage first, being as potential candidates: the 
complement-mediated cell damage, direct activation of platelets, pro-coagulative state 
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in the endothelium, dysregulation of the coagulation or thrombolytic pathways, and 
direct complement-independent cell damage.(11) 
CLINICAL MANIFESTATIONS 
The consequence of thrombosis and ischemic injury of multiple organs is seen on aHUS 
clinical manifestations.(1) Symptoms are consistent with severe MAHA, 
thrombocytopenia and acute renal failure such as pallor, fatigue, decreased urine output 
and edema. Hypertension, which results of hyperreninemia and volume expansion,  can 
be a new onset or an exacerbation of a previously known disease.(10) 20% of the patients 
can present extra-renal manifestations, such as neurological symptoms (like altered 
conscious, focal neurologic deficits, seizures, encephalopathy, hemiparesis, visual 
abnormalities, hemiplegia and coma), cardiovascular manifestations (myocardial 
infarction, myocardiopathy, heart failure, and peripheral ischaemic vasculopathy) and 
gastrointestinal signs (prodromic diarrhea, colitis, nausea, vomit, abdominal pain, 
hepatitis, cholestasis and pancreatitis).(5, 6, 8) Even though the presentation is often 
abrupt, aHUS progression can be insidious in 20% of the cases.(1)  
Laboratory findings include anemia, high levels of lactate dehydrogenase (LDH), 
reduced haptoglobin levels and the presence of schistocytes on a peripheral blood smear 
(all related to MAHA), thrombocytopenia, elevated serum creatinine level, mild 
proteinuria and microscopic hematuria.(1, 5, 6) Prothrombin and partial thromboplastin 
times are normal, serum C4 concentration is normal and C3 levels may be reduced.(1, 10)  
 
aHUS is impossible to distinguish from typical HUS on standard histological analysis.(2) 
In the acute phase endothelial cell swelling and detachment frequently come along with 
thrombosis, although thrombi are not essential to a histological diagnosis of aHUS.(1) 
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Fibrinoid necrosis can be found in glomerular capillaries and arterioles, consisting of 
fibrin, cellular debris and rare neutrophils.(1) Glomerular capillary and arterioles wall 
thickening are often observed because the integrity of the vascular endothelial cells is 
lost, leading to accumulation of plasma proteins in the subendothelial zone. If a 
comparable material accumulates in the mesangium, mesangiolysis and glomerular 
capillary aneurysms can occur.(17)  Finally, mucoid intimal hyperplasia narrows the 
vascular lumen. (8) Immunohistological examination shows erratic deposition of fibrin, 
IgM, C3 and C1q in affected areas.(1)
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS 
The first step of the diagnosis approach of a thrombotic microangiopathy patient is to 
distinguish between STEC-HUS, aHUS and thrombotic thrombocytopenic purpura 
(TTP).(8) A complete clinical history, including family medical history, physical 
examination and hematological, biochemical and microbiological assays should be 
performed.(17) However, all blood samples must be executed before PT.(6) 
 
When comparing STEC-HUS with atypical HUS there are some similarities to consider, 
such as the clinical signs and symptoms.(10, 11) Furthermore, the pathogenesis is 
identical, since endothelial cells, red cells and platelets are affected in both entities.(11)  
A positive Shiga toxin teste in stool samples and a positive Sorbitol-MacConkey stool 
culture (detecting E coli O157:H7, the most common STEC) validate the diagnosis of 




The Coombs test must be also undertaken, and in case of a positive result, the 
possibility of pneumococcal HUS must be considered.(10) 
Establishing the diagnosis of TTP or HUS based only in clinical criteria isn’t reliable 
because of the similarity of both presentations.(15) Therefore to exclude TTP it´s 
mandatory to confirm a normal ADAMTS13 (a disintegrin and metalloproteinase with 
thrombospondin type 1 motif 13) activity (>5-10% ).(6, 10)  
Scleroderma renal crisis, antiphospholipid syndrome, malignant hypertension, 
malignancy-related TMA, methylmalonic aciduria, homocystinuria type C disseminated 
intravascular coagulation (DIC) and HELLP (hemolysis, elevated liver enzymes, and 
thrombocytopenia) syndrome are other forms of TMA that must be excluded.(1, 5) 
The diagnosis of aHUS is a diagnostic of exclusion.(6) The hematological and 
histological findings referred above are important when suspicion of aHUS diagnosis is 
made, albeit in some cases, schistocytes could be absent and platelet count or serum C3 
concentration may be normal. (1, 6) Elevated serum C3 concentration is present in 30 to 
50% of aHUS cases but could also point to a C3 glomerulopathy (C3G), highlighting 
the importance of renal biopsy for diagnosis. Contrary to aHUS, C3G follows a chronic 
and indolent progression with persistent alternative pathway activation, resulting in 
predominant glomerular C3 fragment deposition and a 10-years renal survival rate of 
nearly 50%.(7) 
Complement analysis requires serum levels of C3, C4, CFH, and CFI.(8) In aHUS 
patients is expected a normal CH50 value (antibody-coated sheep erythrocyte lysis 
assay that determines the total complement activity) and a reduced AP50 level (a rabbit 
erythrocyte lysis assay that determines the alternative complement activity). Individuals 
whit FH mutation or FH autoantibodies present an abnormal CFH functional assay with 
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sheep erythrocytes lysis. A new functional assay called modified Ham test has been 
recently suggested as promising test for the distinction of aHUS from STEC-HUS, TTP 
and DIC, highlighting future improvement in the diagnostic of TMA..(10) 
Screening for MCP mutations can be made by a fast and an inexpensive method, such 
as by flow cytometry on mononuclear cells, although genetic analysis is still required to 
detect all changes.(8) 
Nowadays, the diagnosis of aHUS is based on genetic studies, even though the 
proportion of variants identified are still a challenge due to the uncertainty of its clinical 
significance. Further functional assays are needed to evaluate its relevance.(8, 10) Despite 
that, genetic screening in these patients has also diagnostic and prognostic relevance and 
might influence the natural course and the long-term management of the disease. (10)  
Renal biopsy is not indicated in patients with a solid diagnosis of aHUS (e.g. positive 
family history or recurrence) due to the risk of bleeding. However, it may be needed for 
acute renal failure in adult patients to verify the etiology, exclude other processes and 
assess the prognosis.(6)  
TREATMENT 
A thrombotic microangiopathy should be assumed as a medical emergency, and 
treatment should be applied within the first 24 hours to guarantee safe conditions to stop 
and revert TMA progression. (18) These first measures include PT, management of renal 
failure including evaluation of dialysis need, control of hypertension and fluid status 
(since hypervolemia and acute pulmonary edema are frequent complications). Red 
blood cells transfusions are often required to control anemia. Indication for platelet 
transfusion is controversial due to potential thrombotic manifestations exacerbation.(2, 6)  
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The etiology may be unclear so it´s important to contemplate all possible diagnosis and 
triggers, collect laboratory tests and prompt treatment initiation. Even though some of 
the results take several days (ADAMTS13 activity level, CH50, C3, C4, FH and FI 
levels, FH autoantibody level) or even months (genetic studies) to be available, it 
should not delay treatment initiation, as well as further adaptations according to the 
therapeutic response and lab results.(10) Fig.3 and Fig.4 present algorithms of the 
management and treatment of these patients and renal transplantation approach, 
respectively, but there are no consensual guidelines relatively to the long-term treatment 
options. 
PT can be supplied as plasma exchange (PE) or plasma infusion (PI). Both approaches 
have been crucial for mortality decrease (from 50% to 25%) in the last 3 decades.(1, 6, 10) 
In PE, the patient plasma is replaced with non-native frozen plasma (FFP), with high 
doses of complement-regulating proteins. This exchange leads to an elimination of 
dysfunctional endogenous soluble complement inhibitors, FH autoantibodies and 
inflammatory/thrombogenic factors implicated in endothelial damage and platelet 
hyper-aggregation, explaining why PE is more effective than solely PI.(2, 9)  
Moreover PE permits a provision of larger volumes of plasma comparing with PI, 
avoiding fluid overload.(2) Based on the European guidelines, PE should start with early 
and high volumes (1.5 to 2 plasmatic volume/day, or 60 to 75ml/kg of body weight per 
session) daily for 5 days, then 5 sessions/week for 2 weeks and 3 sessions/week for 2 
weeks.(19) When hemolysis became contained and platelet count stabilized PE can be 
gradually tapered. Patients with genetic defects usually need long-term plasma therapy 
(twice a week or weekly based regimens) to maintain remission.(6, 8)  
Complications of this therapy exist especially with low-weight patients (specially 
children) which more prone to the development of symptomatic hypervolemia. 
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Hypotension, allergic reactions, catheter-related complications (thrombosis and 
infection), and hypocalcemia are the most frequent complications with PE therapy.(20) 
In PI patients receive FFP and functional complement regulators (20 to 30ml/kg of body 
weight) but there is no replacement, so it doesn’t remove the abnormal factors that 
modify the complement system function, reducing its efficacy.(1, 6) Anaphylactic 
reactions to FFP, hypervolemia, high blood pressure, heart failure, or hyperproteinemia 
are the main complications.(6) 
Therapy response (either PE or PI) varies largely according to each mutation and seems 
to be higher with C3, thrombomodulin mutations and FH autoantibodies comparing to 
CFH or CFI mutations.(10) PT may induce remission in complement factor H (CFH) 
mutations, yet after long-term therapy it may become unresponsiveness. Complement 
factor I (CFI) mutations have also a partial response, with only 30 to 40% of 
remissions. Complement factor B and C3 mutations achieve rates of 30 and 50% of 
response respectively, but patients carrying these mutations will need more regular 
plasma exchanges to eliminate the hyper-functional mutant proteins.(2)  
CFH autoantibodies are cleared in PE so this therapy can be used to improve the results 
in these patients since high antibody titers are associated with a higher risk of relapse. 
The rational for PE combination with immunosuppressive agents, in this group of 
patients, is justified by the reduction of antibody production.(6)  
MCP is a transmembrane glycoprotein, surface-bound complement regulatory protein 
that acts as a cofactor for the CFI-mediated cleavage of C3b and C4b that are deposited 
on host cells. Patients with MCP mutations carry the best prognosis albeit plasma 
treatment did not impact the outcome significantly: remission was achieved in around 
90% of both plasma-treated and plasma-untreated acute episodes. Renal transplantation 
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outcome is more favorable in patients with MCP mutations, than in patients 
with CFH and CFI mutations due to disease recurrence in the last ones.(2, 10)  
The clinical response after 5-7 days of daily PT treatment should aid further decisions 
since the complete hematological response and renal recovery rates are usually below 
50% and differ according to the type of mutations or the levels of antibody titers.(5, 9) 
The explanation for that low recovery rate relies on the facts that PT doesn’t inhibit the 
underlying complement-mediated pathogenic mechanism or prevent progression of 
tissue damage.(21)  
Patients with cancer are an exception since PT will not improve the outcome in these 
cases, highlighting the importance of the neoplastic disease control.(18) 
The American Society for Apheresis (ASFA) present guidelines with plasma therapy 
indications, which are graded from I to IV, being category I a 1st line indication to PT 
based on the evidence and category IV when the evidence shows ineffective results. 
Since aHUS due to CFH autoantibodies fits in the category I, early PT is vital on the 
syndrome management.(5) In cases of incomplete response, maintenance of MAHA and 
absence of renal recovery eculizumab may be considered.(5, 8) However, the most 
effective approach is currently not consensual.(6) 
Eculizumab is a recombinant humanized monoclonal antibody that by a high affinity 
binding to C5 blocks the cleavage into its effectors C5a and C5b and stops the 
membrane attack complex formation.(22) Regardless the type of mutation or complement 
anomaly eculizumab can be effective, given that C5 is a terminal complement 
component.(1) However, recent studies showed a residual activity of the terminal 
pathway through alternative pathway activation and elevated C5a levels in patients 
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treated with eculizumab, since it fails to block C5a resulting from direct enzyme 
cleavage by trypsin and thrombin .(23, 24) 
Extensive trials, prospective studies and case reports demonstrated the effectiveness of 
eculizumab, reporting that about 85% of the patients became disease-free, even in those 
plasma-resistant.(6, 8, 25) Results in long-term also showed a stabilization of the platelet 
count with a decrement no more than 25% from the baseline, allowing PT 
discontinuation. Moreover, improvement of renal function with dialysis suspension in 
some cases was also observed, as well as a higher quality of life, safety and 
tolerability.(1, 26) Eculizumab also demonstrate satisfactory results relatively to 
complement-related, inflammation and endothelial activation biomarkers, even though 
some of them did not completely normalize, emphasizing the constant risk of chronic 
activation of complement system in aHUS patients.(6) However, for aHUS patients 
carrying DGKᶓ mutation eculizumab doesn’t seem to be effective.(11) Familial history of 
HUS, relapsed aHUS, high-risk genotypes, renal transplantation, resistance or 
dependency on plasma therapy are factors that favor the use of eculizumab.(10) 
Furthermore treatment with eculizumab should started be as early as possible, soon after 
STEC-HUS and TTP diagnosis exclusion.(27) Note that some trials demonstrate a 
correlation inversely proportional between the improvement of the estimated glomerular 
filtration rates and the time between the clinical manifestations and the beginning of the 
drug.(6) The recommended dose in adults is 900mg per week intravenous infusion, for 4 
weeks (induction phase), followed by a 5th dose of 1200mg after 7 days, and afterwards 
1200mg every 14 days (maintenance phase).(28) Patients who are also receiving PE 
should do an extra dose of 600mg of eculizumab after each plasma session.(10) The 
length of the treatment it’s not clearly established but cumulative experience may 
facilitate consensus in treatment strategies.(27) The assessment of response to 
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eculizumab is based on monitoring disease activity markers like platelet counts, lactate 
dehydrogenase, haptoglobin, serum creatinine and complement activity markers.(29) 
When complement inhibition is successful, it´s observed considerable reductions of the 
hemolytic complement function: the classical (CH50), the alternative pathway 
(APH50), and the C3d and sC5b-9 levels, while C5a levels diminished only 6 months 
after eculizumab. Drug accumulation can be demonstrated by serum concentration of 
eculizumab (level over to 1082 μg/ml). Specific enzyme-linked immunosorbent assay 
(ELISA) is also a way to determine eculizumab concentration. (30) Long-term treatment 
is recommended in renal transplantation, in high-risk genotypes, and in severe extra-
renal findings. Several authors suggest life-long treatment with eculizumab, due to its 
the favorable side-effect profile.(8, 31)  
Some studies reported eculizumab deposition in glomeruli with anti-eculizumab 
antibody production but the long-term significance is unclear.(32)  
The decision for eculizumab withdrawal must take in account the risk of recurrence, the 
type of mutation, the patient age, the renal function and extra-renal manifestations. The 
patient must be closely monitored and in the presence of relapse, re-administration 
should be prompt initiated.(33) Regular self-monitoring of hemoglobinuria through urine 
dipsticks has been recently introduced as a form to quickly detect aHUS relapses after 
discontinuation of eculizumab.(34)  
Treatment with eculizumab has an annual cost of 700,000$ approximately and 
laboratory assays to optimize the treatment are lacking, so Kerboua. K, et al suggested a 
novel disease activity marker, C3:CH50 ratio, to use during the induction and 
maintenance phase.(35, 36) 
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Because of the augmented risk of infection by encapsulated organisms of patients under 
eculizumab treatment, tetravalent vaccine against Neisseria meningitidis (A, C, Y, 
W135) as well as vaccination against serogroup B two weeks before eculizumab 
treatment is mandatory. After that, patients should receive prophylactic antibiotics 
(penicillin V potassium at 250 mg every 12 hours or ciprofloxacin 500 mg daily during 
4 weeks). (37) At least two months after the first vaccine a booster dose should be 
performed.(10) When the postponement of eculizumab treatment until vaccine response 
isn’t possible associated treatment with antibiotics against N. meningitides may be 
initiated and antibiotic prophylaxis may be instituted according the hospital protocol.(6) 
To immunocompromised patients it should be given continued antibiotic prophylaxis as 
long as eculizumab treatment last.(37) Vaccination against Haemophilus influenzae type 
b is recommended annually to all patients and vaccination against Pneumococcus 
pneumoniae should also be considered in children case.(5, 10) During active infections, 
eculizumab should be suspended if possible. Counseling and screening for gonococcal 
infection should be performed after and during treatment in sexually active patients, 
mainly in high risk patients, and in their partners.(37) 
The most common adverse effects of eculizumab include cough, headache, nausea, 
vomiting, diarrhea, hypertension, upper respiratory tract infections, urinary tract 
infections and abdominal pain.(1) Hepatotoxicity, a pediatric side-effect, was also 
described in an adult patient.(38) 
Despite the best results with eculizumab, this treatment costs 4800-6500€ per 300mg, 
being four times more expensive than PE (850-1800€ per session) and making it 
inaccessible to many low-resource settings.(39) 
The outcome of renal transplantation in aHUS patients is variable, having a straight 
correlation with the genetic abnormality involved as shown on Tab.1.(40) For instance 
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CFH, CFI, C3 and CFB mutation carriers have abnormal complement regulators, most 
of them synthetized in the liver, with high recurrence rate, reaching up to 80% of the 
cases.(41) On the other hand, MCP mutations carries more favorable outcomes, with free-
recurrence rates of 80%, being suggested that the individuals who recur have an 
additional genetic predisposition.(8) These good results can be explained because MCP is 
a transmembrane protein highly expressed on kidney, so the defect is corrected when 
kidney transplant is performed.(42)  
Post-transplant aHUS recurrence occurs in 60 to 90% in the first year after transplant 
and graft-survival is only 51%.(43) It may be triggered by brain-death related injury, 
ischemia-reperfusion injury, infections (cytomegalovirus, influenza virus, parvovirus 
B19, BK virus, upper respiratory tract infections and infectious gastroenteritis), the use 
of immunosuppressive drugs (calcineurin inhibitors, mTOR inhibitors) or rejection.(44)  
There are limited data on the efficacy of prophylactic plasma therapy including 
plasmapheresis to prevent post-transplant aHUS recurrence. Nevertheless, the progress 
in genetic studies and the introduction of eculizumab allowed renal transplantation in 
highly risk patients.(1, 8) Albeit the promising results published in some living donor 
transplantation cases with prophylactic eculizumab regimens, living donation isn’t 
consensual. The risk for the presence of mutations or polymorphisms still not detectable 
in the potential living donors is a concern and may justify the cases of aHUS in healthy 
donors, probably triggered after the donation procedure.(43)  
Beyond PE and eculizumab, there are other therapeutic options in order to avoid 
recurrence after renal transplantation such as liver-kidney combined transplantation and 
the use of antibody-suppressing or depleting agents (corticosteroids, azathioprine, 
mycophenolate mofetil, cyclophosphamide or rituximab). These agents have shown 
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important results relatively to CFH autoantibodies control, especially with rituximab. 
The absence of aHUS recurrence, normalized graft function and negative titers in 
previous studies using rituximab, turned it into a beneficial prophylactic choice to 
patients with persistently elevated CFH autoantibodies titers, even when renal 
transplant is not performed.(10, 42)  
Recombinant-human C1 inhibitor (C1-INH) is being tested as therapy for antibody-
mediated rejection and to prevent ischemia-reperfusion injury.(41)  
Since complement plasma factors like FH, FI, FB and C3 are mainly synthesized in the 
liver, it seemed logical that combined renal and liver transplantation could correct the 
genetic deficiency and so normalize the activity of fluid-phase complement regulatory 
proteins.(6, 8) However, the results were not so promising, leading to ischemia-
reperfusion injuries, post-transplant recurrence and fatal encephalopathy, with 10-20% 
of short-term mortality.(2, 6, 8) The high morbidity and mortality associated to this 
procedure, and the organ shortage, make this option a rare indication.(6) When 
contemplated, screening for mutations, prophylactic eculizumab or PE, in addition to 
aspirin and heparin, must be performed.(2, 6, 8)  
Calcineurin (CNI)-free regimens has been attempted in a few reports, based in 
Belatacept regimens, with favorable short-term outcomes. (42) The rationale for those 
protocols aim to reduce the introduction of potential drug triggers. 
The treatment of post-transplant recurrence consists in early initiation of PE or 
eculizumab.(42) However, new treatments and approaches are arising in the aHUS field.  
SKY59, a novel humanized antibody has a long-lasting neutralization of C5 activity 
comparing to eculizumab.(45) Studies with recombinant factor H also demonstrated 
optimistic results in the treatment of patients with CFH deficiency.(1, 2) Inhibitors of 
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angiotensin-converting enzyme, statins (HMG-CoA reductase), ascorbic acid and 
allopurinol (inhibitor of xanthine oxidase) are also potential adjuvant agents for aHUS 
treatment since they reduce the oxidative inactivation of nitric oxide, increasing nitric 
oxide availability and promoting the endothelium-dependent vasodilation.(1) Other new 
options are the oral CCX168  (C5aR antagonist), currently in a phase 2 trial, and a 
small-molecule factor D inhibitor that successfully inhibited alternative complement 
pathway by binding human Factor D and inhibiting its proteolytic activity against 
purified Factor B in complex with C3b.(5, 46, 47)  
EVOLUTION AND PROGNOSIS 
aHUS is prone to a poor prognosis, due to the underlying genetic defect, whose 
recognition is essential for risk stratification after renal transplantation as shown on 
Tab-1.(8) ESRD, extra-renal symptoms, number of recurrent episodes after renal 
transplantation and the delay time until prompt initiation therapy, also change the 
prognosis.(10) Despite that, aHUS prognosis is reserved with high rates of mortality 
(25% in the acute phase), end-stage renal disease (50% within a year) and recurrence.(1)  
CONCLUSION 
The perspectives of treatment aHUS changed drastically in the past few years, after 
eculizumab introduction in the therapeutic armamentarium, providing a useful tool in 
aHUS PE resistant or dependent, as well in renal transplantation. Nevertheless, the cost 
remains a major obstacle for its generalized implementation, leaving PE as the only 
therapeutic option available in many centers. Moreover, consensual guidelines with 
precise eculizumab indications and management strategies are needed in order to 
provide adequate follow-up of this diverse group of patients. 
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Further information about the genetic and the pathophysiology of aHUS is crucial for 
the development of therapeutic strategies and, as a consequence, new therapeutics 
molecules acting on specific targets in complement system may provide promising 
results in the near future.  
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TABLES AND FIGURES: 
 Table 1. Atypical hemolytic uremic syndrome: genetic modifications, 
clinical characteristics and prognosis.   
 
RT: renal transplantation; ESRD: End-stage renal disease; ¥Without prophylactic therapy 








Figure 1. The alternative pathway of the complement system and the 
action of eculizumab.  
 
The alternative pathway (AP) of the complement system is continuously activated low-
activated in plasma, finishing with the formation of the membrane-complex attack (MAC) and 
with the release of powerful anaphylotoxins (C5a). In the beginning of the process, C3(H2O) 
binds factor B (CFB), which is cleaved bi factor D (CFD), and form the alternative pathway 
initiation C3 convertase. This is responsible to cleave C3 into C3a and C3b. C3b and hydroxyl 
groups on cell-surface carbohydrates and proteins of target cells establish a covalent binding 
forming the amplification loop C3 convertase. This C3b also binds CFB and form another 
amplification loop C3 convertase (on the fluid phase). Cleavage of C3 molecules by C3 
convertase enzymes ends on another feedback amplification loop. At least, C3b binds to 
C3bBb creating the C5 convertase enzyme, responsible to cleave C5 into C5a and C5b which 
will be part of the MAC. This mechanism is extremely regulated by complement factor H 
(CFH), complement factor I (CFI), complement receptor 1 (CR1), decay accelerating factor 
(DAF) and membrane cofactor protein (MCP) in a way to prevent host cell injury and control 
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the deposition of complement in pathogens cell surface. CR1 and CFH both perform as 
cofactors for CFI, leading to a cleavage of C3b and a decrease of the C3 convertase. MCP 
binds to C3b preventing its connection to other factors and DAF is responsible to dissociate 
C3 and C5 convertases. Eculizumab is a monoclonal antibody that that by a high affinity 
binding to C5 blocks the cleavage into its effectors C5a and C5b and stops the membrane 














Figure 2. Cycle and parallel processes and the action on the cells of the 
complement system activation in aHUS. 
The dysregulated activation of the complement system happens where there are abnormal 
regulator proteins (CFH, CFI or MCP) or overactive mutated complement factors (CFB, C3), 
leading to the release of anaphylotoxins (C5a) and to the membrane attack complex (MAC) 
formation. In red cells, this ends with release of the hemoglobin and decrease of the nitric 
oxide (NO) in plasma. Platelet activation and aggregation and augmented tissue factor (TF) 
activity on the endothelium are also a consequence of this complement processes. These 
mechanisms lead to a procoagulative state, coagulation and tissue impairment. The feedback 
loops observed could explain the cyclical and parallel characteristics of this phenomena. 
Thrombomodulin, diacylglycerol kinase ɛ (DGKɛ) and plasmin are also responsible to control 
these mechanism, and abnormalities in these proteins can also be an explanation to the 
pathogenic processes in aHUS.  
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Figure 3. Diagnosis and treatment algorithm for the management of a 
patient with thrombotic microangiopathy (TMA) 
 
Supportive treatment is mandatory and includes, besides fluid management, red blood cells 
transfusion, renal replacement therapy and intensive care unit admission if necessary. Platelet 
transfusion should be avoided since it could aggravate the TMA. TMA approach should star to 
exclude TTP and STEC-HUS by ADAMST13 activity assays and Stec detection, respectively. 
Because of the high mortality rates of TTP if untreated, early plasma terapy (PT) should be 
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instituted in adults but since TTP is rare in children, first line treatment could be eculizumab if 
aHUS is supected. A complete clinical history should also be colected to establish potential 
triggers/causes. Evidence suggesting a complement etiology could include familiar history or 
previous aHUS episodes and in those cases we could performe a complement study, stop PT 
and start eculizumab if possible. If eculizumab isn’t available, continuation of PT therapy or 
renal transplant could be considered. When the patient has elevated FH antibody titers, a 
combined therapy with rituximsb or other immunosuppressive agent could be contemplated. 
ADAMTS13: a disintegrin and metalloproteinase with a thrombospondin type 1 motif, 
member 13; aHUS: atypical hemolytic uremic syndrome; DGKE: gene encoding 
diacylglycerol kinase; CFH: complement factor H; CFI:complement factor I; CFB: 
complement Factor B; HUS: hemolytic uremic syndrome; LDH: lactate dehydrogenase: MCP: 
membrane cofactor protein; PE: plasma exchange; PT: Plasma therapy; STEC: shiga toxin–
producing Escherichia coli; Stx: shiga toxin;THBD: Thrombomodulin; TMA: thrombotic 





Figure 4. Atypical hemolytic uremic syndrome management algorithm for 
patients eligible for renal transplantation. 
 
 
ESRD: end-stage renal disease; MCP: membrane cofactor protein; DGKɛ: diacylglycerol 
kinase ɛ; FH: Factor H; CFH: complement factor H; CFI: complement factor I; CFB: 
complement factor B; aHUS: atypical hemolytic uremic syndrome; RT: renal transplantation; 
PT: plasma therapy (in these plasma exchange should be performed). * Living donor 
transplantation is controversial and should only be considered when eculizumab is available.  
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Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in
line with normal text where possible and use the solidus (/) instead of a horizontal line for small
fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often
more conveniently denoted by exp. Number consecutively any equations that have to be displayed
separately from the text (if referred to explicitly in the text).
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Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word
processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate
the position of footnotes in the text and list the footnotes themselves separately at the end of the




• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or
use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately in the Figure Legends section of the manuscript..
• Size the illustrations close to the desired dimensions of the printed version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then
please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is
finalized, please 'Save as' or convert the images to one of the following formats (note the resolution
requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of
500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a
low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. Further information on the preparation of
electronic artwork.
Illustration services
Elsevier's WebShop offers Illustration Services to authors preparing to submit a manuscript but
concerned about the quality of the images accompanying their article. Elsevier's expert illustrators
can produce scientific, technical and medical-style images, as well as a full range of charts, tables
and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve
them to a professional standard. Please visit the website to find out more.
Figure legends
Ensure that each illustration has a legend. Supply legends separately, not attached to the figure. A
legend should comprise a brief title (not on the figure itself) and a description of the illustration. Keep
text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
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Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules and shading in table cells.
Permissions
If any illustration or table has been previously published, a copy of the letter of PERMISSION to reprint
from the copyright holder must accompany the manuscript (a sample Permission Request Form can be
found at http://www.elsevier.com/journal-authors/obtain-permission ). The source of the illustration
or table should be included in the reference section of the manuscript. The legend should conclude with
“Reprinted with permission” followed by the reference number, eg, “Reprinted with permission.23”
Authors are responsible for any permission fees requested by the copyright holder.
Do not submit the same illustration or table simultaneously to two publishers on the assumption that
one article will publish before the other and that the publisher of the first article will grant permission
for reuse of the material. Publication of one article may be delayed unexpectedly, necessitating
withdrawal of material from the other article at a late stage of production, which would delay
publication of the issue.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Reference numbers (citations) in the text follow numerical order and should be superscripted.
References are listed according to their order in the text, not in alphabetical order. The maximum
number of references is 100.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to
the sources cited. In order to allow us to create links to abstracting and indexing services, such as
Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please
note that incorrect surnames, journal/book titles, publication year and pagination may prevent link
creation. When copying references, please be careful as they may already contain errors. Use of the
DOI is encouraged.
A DOI can be used to cite and link to electronic articles where an article is in-press and full citation
details are not yet known, but the article is available online. A DOI is guaranteed never to change,
so you can use it as a permanent link to any electronic article. An example of a citation using DOI
for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M.
(2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal
of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such
citations should be in the same style as all other references in the paper.
Please note that manuscripts in press may be referenced; however, manuscripts that have been
submitted for publication but not yet accepted should not be referenced. All references must be
complete when the manuscript is submitted.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
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Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them
in your text and including a data reference in your Reference List. Data references should include the
following elements: author name(s), dataset title, data repository, version (where available), year,
and global persistent identifier. Add [dataset] immediately before the reference so we can properly
identify it as a data reference. The [dataset] identifier will not appear in your published article.
References in this issue
When referring to another article in the Seminars issue, incorporate it as an In Press article and the
page numbers will be added by the editorial staff prior to printing.
Reference style
Text: Indicate references by (consecutive) superscript arabic numerals in the order in which they
appear in the text. The numerals are to be used outside periods and commas, inside colons and
semicolons. For further detail and examples you are referred to the AMA Manual of Style, A Guide for
Authors and Editors, Tenth Edition, ISBN 0-978-0-19-517633-9.
List: Number the references in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun.
2010;163:51–59.
Reference to a book:
2. Strunk W Jr, White EB. The Elements of Style. 4th ed. New York, NY: Longman; 2000.
Reference to a chapter in an edited book:
3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith
RZ, eds. Introduction to the Electronic Age. New York, NY: E-Publishing Inc; 2009:281–304.
Reference to a website:
4. Cancer Research UK. Cancer statistics reports for the UK. http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/; 2003 Accessed 13 March 2003.
Reference to a dataset:
[dataset] 5. Oguro, M, Imahiro, S, Saito, S, Nakashizuka, T. Mortality data for Japanese oak wilt
disease and surrounding forest compositions, Mendeley Data, v1; 2015. https://doi.org/10.17632/
xwj98nb39r.1.
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.
Video
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
relate to the video file's content. . In order to ensure that your video or animation material is directly
usable, please provide the file in one of our recommended file formats with a preferred maximum
size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in
the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply
'stills' with your files: you can choose any frame from the video or animation or make a separate
image. These will be used instead of standard icons and will personalize the link to your video data. For
more detailed instructions please visit our video instruction pages. Note: since video and animation
cannot be embedded in the print version of the journal, please provide text for both the electronic
and the print version for the portions of the article that refer to this content.
Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your
article to enhance it. Submitted supplementary items are published exactly as they are received (Excel
or PowerPoint files will appear as such online). Please submit your material together with the article
and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to
supplementary material during any stage of the process, please make sure to provide an updated file.
Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option
in Microsoft Office files as these will appear in the published version.
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Submission Checklist
The following list will be useful during the final checking of an article prior to sending it to the journal
for review. Please consult this Guide for Authors for further details of any item.
• Ensure that the following items are present:
• One author has been designated as the corresponding author, with contact details:
• E-mail address
• Full postal address
• Phone numbers
• Disk is enclosed
• The electronic version and the hardcopy of the manuscript are identical
• Disk has been labelled with
article details (first author, first words of title)
file name(s)
media format (e.g., PC, Mac)
file format (e.g., Word, LaTeX)
• All text pages
• Keywords
• Original artwork (high-quality prints)
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color reproduction on the Web (free of charge)
and in print (a charge will apply), or to be reproduced in color on the Web (free of charge) and in
black-and-white in print
• If only color on the Web is required, black and white versions of the figures are also supplied for
printing purposes
For any further information please visit our customer support site at: http://support.elsevier.com.
AFTER ACCEPTANCE
Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do
not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the
e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF
proofs which can be annotated; for this you will need to download the free Adobe Reader, version 9
(or higher). Instructions on how to annotate PDF files will accompany the proofs (also given online).
The exact system requirements are given at the Adobe site.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies
to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line
number. If, for any reason, this is not possible, then mark the corrections and any other comments
(including replies to the Query Form) on a printout of your proof and scan the pages and return via e-
mail. Please use this proof only for checking the typesetting, editing, completeness and correctness
of the text, tables and figures. Significant changes to the article as accepted for publication will only
be considered at this stage with permission from the Editor. We will do everything possible to get your
article published quickly and accurately. It is important to ensure that all corrections are sent back
to us in one communication: please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Three free copies of the issue will also be sent to the corresponding author of each article.
Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free
access to the final published version of the article on ScienceDirect. The Share Link can be used
for sharing the article via any communication channel, including email and social media. For an
extra charge, paper offprints can be ordered via the offprint order form which is sent once the
article is accepted for publication. Both corresponding and co-authors may order offprints at any
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time via Elsevier's Webshop. Corresponding authors who have published their article open access do
not receive a Share Link as their final published version of the article is available open access on
ScienceDirect and can be shared through the article DOI link.
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